Hollis O Neal, MD
Pulmonary Disease · Baton Rouge, LANPI 1497896823
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $415,800 of the $417,629 with a category attached, or 99.6%. Cytovale, Inc. accounts for 100.0% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $417,559, more than ten times the $18 reported in 2020. Among pulmonary disease clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $32,125 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cytovale, Inc.$418K
- Sanofi$37
- Paratek Pharmaceuticals, Inc.$18
- AstraZeneca$14
Across 5 payments — averaging $52,871 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$252K
- Shionogi Inc$13K
What the payments were for
- Consulting fees$415,800100%
- Travel & lodging$1,0900%
- Food & beverage$7390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cytovale, Inc. | 10 | $417,559 |
| Sanofi | 1 | $37 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| AstraZeneca | 1 | $14 |
How this compares
$417,629 in reported general payments places this provider in the 95th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $143,244 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,780 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Baton Rouge
- Robert HinkleBaton Rouge$19K
- Tarek AbdallahBaton Rouge$12K
- Alexander MulamulaBaton Rouge$12K
- Brad VincentBaton Rouge$12K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Warren BotnickNatchitoches$213K
- Nicole LapinelNew Orleans$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.